Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4896)	11/7/2001 1:57:44 PM
From: aknahow	Read Replies (1) of 52153

Never posted anything, at S.I., about the last BGEN release which estimated sales of Amevive reaching $500 million three years from approval. In the same release BGEN pushed back the launch of Amevive until late 2002 or first quarter 2003. But, was very interested in hearing what others thought, given that at conferences, Amevive was said to be a billion dollar drug. Long time ago I posited that if the duration was as long as claimed then this would work against sales. Or is there some other reason? Is the market now seen as smaller? Competition from several others, stronger? The issue of the possible need for a license from DNA has never again been mentioned, but it may appear in their third quarter S.E.C. filing as it did in the second quarter, but perhaps with an update. BGEN provided no explanation for the new estimated approval date. But, BGEN got a free ride from the financial press. Even the one broker downgrade mentioned neither the delay nor the 50% reduction of potential market for Amevive.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next